Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share plan transaction rather than a financial results report.
Material Changes
The filing discloses an increase in notional interests in Ordinary shares for a connected person. Specifically, on October 11, 2011, the Administrators of the Performance Share Plan notified the company of a transaction involving Mrs. K Thomson (connected to Director Mr. P C Thomson). The transaction involved an increase of 24,963 Ordinary shares at a price of 1,365 pence per share, resulting from the notional re-investment of the dividend paid on October 6, 2011.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, or outlook regarding future performance. It notes that notional dividends accrued will be paid out in proportion to the percentage of the participant's Performance Share Plan holdings that vest following the end of the relevant three-year measurement period. The transaction was notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Investor Verification Points
- Verify the vesting schedule and conditions for the GlaxoSmithKline Performance Share Plan to understand the timing of potential payouts.
- Confirm the total number of shares held by Mr. P C Thomson and Mrs. K Thomson following this notional increase.
- Review the dividend payment details for October 6, 2011, to validate the basis for the notional re-investment.